Notably, treatment with investigational anticancer agents such as AICAR, an AMPK activator, and PI-103, a dual PI3K/mTOR inhibitor, was shown to restore GSTM5 expression and increase treatment sensitivity in resistant ovarian cancer cells [38]. Here, GSTM5 is linked to ovarian carcinoma.